KK
VERV

KLP Kapitalforvaltning’s Verve Therapeutics VERV Stock Holding History

KLP Kapitalforvaltning’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,200
Closed -$115K – 2220
2025
Q2 		$115K Sell
10,200
-7,700
-43% -$43.9K ﹤0.01% 2001
2025
Q1 		$81.8K Hold
17,900
– – ﹤0.01% 2093
2024
Q4 		$101K Buy
+17,900
New +$101K ﹤0.01% 2082

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KLP Kapitalforvaltning's VERV Position: Q3 2025 in Review

KLP Kapitalforvaltning sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 10,200 shares — an estimated $115K sold.

KLP Kapitalforvaltning first reported a position in VERV in Q4 2024 and held it in 3 quarters. The position peaked at $115K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • KLP Kapitalforvaltning reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • KLP Kapitalforvaltning sold 10,200 Verve Therapeutics shares in Q3 2025, an estimated $115K.
  • KLP Kapitalforvaltning first reported a position in Verve Therapeutics in Q4 2024 and held it in 3 quarters.
  • KLP Kapitalforvaltning's Verve Therapeutics position peaked at $115K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2025, filed 23 Oct 2025.